Comparison
Liraglutide vs. Matrixyl
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
204656-20-2
214047-00-4
Molecular weight
3751 g/mol
802.06 g/mol
Half-life
13 h
no data
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGPalmitoyl-Lys-Thr-Thr-Lys-SerMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
4
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1